Equillium announces initiation of the phase 3 equator study of itolizumab in first-line acute graft-versus-host disease

La jolla, calif.--(business wire)---- $eq #gvhd--equillium, inc. (nasdaq: eq), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced the initiation of the equator study, a pivotal phase 3 clinical study of itolizumab in patients with acute graft-versus-host disease (agvhd). the randomized, double-blind study will assess the efficacy and safety of itolizumab versus placebo as a first-l
EQ Ratings Summary
EQ Quant Ranking